FDA reverses course, will review Moderna flu shot after controversial refusal

Moderna said the FDA has accepted its application to review mRNA-1010, its experimental mRNA seasonal influenza vaccine, following a Type A meeting after an earlier Feb. 3 “Refusal to File.” The company is seeking full approval for adults 50–64 and accelerated approval for adults 65+ (with an additional required study for the older cohort); if approved the shot could be available for the 2026–27 flu season. The reversal follows public controversy over the initial refusal and accusations of substandard care in parts of the trial, and unfolds amid heightened political scrutiny of mRNA vaccines from federal officials; the decision advances regulatory clarity but leaves approval, post-marketing study requirements and reputational risk unresolved.

Analysis

Market structure: FDA's reversal keeps mRNA flu as a viable disruptor but raises regulatory friction that benefits incumbents (SNY, GSK) short-term; addressable US 50+ seasonal flu market likely in the low-single-digit billions, so a 10–30% share for MRNA implies ~$100–900M revenue/year if approved. Pricing power is muted until CDC/ACIP recommendation and payer coverage; expect continued volatility in MRNA equity and a 20–40% implied-volatility premium in options around milestone dates.

Risk assessment: Tail risks include a final FDA rejection or a mandate for extensive elderly trials (high-impact, <30% probability) that would push launch beyond 2026–27 and wipe out near-term vaccine revenue. Immediate (days) risk = headline-driven 15–30% price moves; short-term (weeks–months) risk = review/adcom outcomes; long-term (quarters–years) risk = politicized policy limiting mRNA funding and uptake. Hidden dependencies: CDC recommendation, Medicare reimbursement, and manufacturing scale are gating factors; catalysts are FDA meeting schedules, ACIP votes, and competitor label expansions.

Trade implications: For immediate risk management, use defined-risk options: buy 3–6 month put spreads on MRNA (long 20% OTM, short 40% OTM) sized to 1–2% portfolio to protect downside to an adverse FDA call. Relative-value: short MRNA vs long SNY or GSK (1:1 dollar-neutral) for a 0–6 month horizon to capture regulatory-risk divergence. If FDA sets a clear approval timeline within 30–60 days, establish a measured 2–3% directional call-spread on MRNA (12-month, long 40% OTM / short 80% OTM) to capture upside.

Contrarian angles: Consensus focuses on headlines; it understates pathway dependence on CDC/Medicare — approval alone may not translate to material uptake without coverage and ACIP backing. Reaction may be overdone if FDA acceptance now means a routine review (underpriced upside) or underdone if politicized oversight triggers delayed labeling (underpriced downside). Historical parallel: vaccine approvals with late political/interagency pushback (e.g., H1N1 timing) produced multi-quarter revenue delays, so position sizing should be conviction- and catalyst-driven.

Key Decisions for Investors

• If long MRNA: size a hedge equal to 1–2% of portfolio by buying a 3–6 month put spread on MRNA (long 20% OTM / short 40% OTM) to cap downside into the next FDA/ACIP milestones; unwind on a confirmed favorable FDA action or after 90 days.
• Speculative upside: conditional on FDA setting a formal review window within 30 days, establish a 2–3% portfolio long via a 12-month call spread on MRNA (buy 40% OTM call, sell 80% OTM call) to capture approval-driven upside while limiting premium paid.
• Pair trade: initiate a 1:1 dollar-neutral pair short MRNA / long SNY (or GSK) sized to 1–2% portfolio for a 0–6 month horizon to exploit regulatory-risk premium in MRNA and defensive vaccine demand for incumbents; tighten if MRNA falls >25% or if SNY/GSK report negative guidance.
• Rotate defensively: increase exposure by 1–2% to large-cap vaccine/consumer-health names (SNY, GSK, PFE) on any extension of regulatory uncertainty >60 days, as these names should see relative inflows if mRNA adoption stalls.